Velusetrag ( DrugBank: Velusetrag )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
99	慢性特発性偽性腸閉塞症	1

99. 慢性特発性偽性腸閉塞症

---

臨床試験数 : 4 /  薬物数 : 9 - (DrugBank : 2) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 4

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-000854-24-IT (EUCTR)	17/09/2021	18/10/2021	Phase II multicenter clinical trial, with treatment randomly assigned, in which patient nor physician are aware of the assigned treatment, active or placebo, to evaluate efficacy and safety of Velusetrag 15 mg (3 x 5 mg capsule) in patients with Chronic Intestinal Pseudo-Obstruction (CIPO)	Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial. - N/A	Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture similar to that of mechanical intestinal obstruction, although in the absence of any lesion occluding the gut. CIPO can be idiopathic or secondary. MedDRA version: 20.0;Level: SOC;Classification code 10017947;Term: Gastrointestinal disorders;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: Velusetrag Product Code: [TD-5108 hydrochloride] INN or Proposed INN: Velusetrag Other descriptive name: THRX-199687 hydrochloride	ALFASIGMA S.P.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	16	Phase 2	Spain;Belgium;Italy